Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Clear Secure Inc (YOU) Price & Performance

Abeona Therapeutics IncTrade
Clear Secure IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Clear Secure Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Clear Secure Inc trades at $49 (market cap $5.28B). The key difference: Clear Secure Inc is far larger — about 12.4× Abeona Therapeutics Inc's market cap, and Clear Secure Inc pays a 1.12% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOYOU
Market Cap
$424.33M$5.28B
Sector
HealthTechnology
52-Week High
$7.45$62.36
52-Week Low
$4.17$29.61
Enterprise Value
$279.23M$4.43B
Dividend Yield
1.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Clear Secure Inc

Clear Secure (YOU) trades at $51.29, down 3.26% in 24 hours, with a bearish technical signal but strong fundamentals including 66.66% gross margins and 90.29% ROE. Recent Q2 2026 earnings beat estimates with EPS of $0.49 versus $0.40 expected, driven by double-digit revenue growth and record free cash flow. The company launched corporate memberships to expand its identity platform, enhancing business travel offerings.

Outlook is mixed: robust profitability and growth initiatives support upside, but high valuation (P/E 34.6) and technical weakness near support at $50 pose risks. Analyst consensus is balanced with 44% buy ratings, yet insider selling and competitive pressures require caution for near-term volatility.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Clear Secure Inc

Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.

Read more on YOU